Gerrit J Wolbink
Overview
Explore the profile of Gerrit J Wolbink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keijser J, Stalman E, Wieske L, Steenhuis M, van Dam K, Kummer L, et al.
EBioMedicine
. 2025 Feb;
113:105620.
PMID: 40010153
Background: Repeated antigen exposure can result in a shifting antibody repertoire. The mechanisms by which this occurs and consequences for cross-variant protection against evolving pathogens remain incompletely understood, particularly in...
2.
Stalman E, Wieske L, Keijser J, van Dam K, Kummer L, Wilbrink M, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):754-766.e7.
PMID: 38763170
Background: Despite impaired humoral response in patients treated with immunosuppressants (ISPs), recent studies found similar severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls. One...
3.
Keijzer S, Oskam N, Ooijevaar-De Heer P, Steenhuis M, Keijser J, Wieske L, et al.
Front Immunol
. 2024 Mar;
15:1314507.
PMID: 38487524
Background: Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies...
4.
Valk A, Keijser J, van Dam K, Stalman E, Wieske L, Steenhuis M, et al.
Allergy
. 2024 Mar;
79(7):1952-1961.
PMID: 38439527
Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be...
5.
van Dam K, Volkers A, Wieske L, Stalman E, Kummer L, van Kempen Z, et al.
BMC Infect Dis
. 2023 May;
23(1):332.
PMID: 37198536
Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral...
6.
van Dam K, Wieske L, Stalman E, Kummer L, Roosen J, van Kempen Z, et al.
J Autoimmun
. 2023 Jan;
135:102984.
PMID: 36621174
For patients with immune-mediated inflammatory diseases (IMIDs), concerns exist about increased disease activity after vaccination. We aimed to assess changes in disease activity after SARS-CoV-2 vaccination in patients with IMIDs,...
7.
van Kempen Z, Hogenboom L, Toorop A, Steenhuis M, Stalman E, Kummer L, et al.
Ann Neurol
. 2022 Oct;
93(1):103-108.
PMID: 36250739
Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if...
8.
Wieske L, van Dam K, Steenhuis M, Stalman E, Kummer L, van Kempen Z, et al.
Lancet Rheumatol
. 2022 Mar;
4(5):e338-e350.
PMID: 35317410
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with specific immunosuppressants. Disease-overarching studies, and data on recall responses and third...
9.
Unger P, Lighaam L, Vermeulen E, Kruithof S, Makuch M, Culver E, et al.
Eur J Immunol
. 2020 Apr;
50(8):1113-1125.
PMID: 32289181
IgG4 antibodies are unique to humans. IgG4 is associated with tolerance during immunotherapy in allergy, but also with pathology, as in pemphigus vulgaris and IgG4-related disease. Its induction is largely...
10.
Atiqi S, Hooijberg F, Loeff F, Rispens T, Wolbink G
Front Immunol
. 2020 Mar;
11:312.
PMID: 32174918
Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either...